Matarin Capital Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Matarin Capital Management’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-121,359	Closed	-$2.34M	–	201
2019 Q4	$2.34M	Sell	121,359 -101,825	-46%	-$1.95M	0.22%	154
2019 Q3	$4.43M	Sell	223,184 -13,560	-6%	-$282K	0.33%	109
2019 Q2	$5M	Buy	236,744 +15,040	+7%	+$314K	0.36%	103
2019 Q1	$4.53M	Buy	221,704 +56,666	+34%	+$1.27M	0.33%	109
2018 Q4	$3.28M	Buy	165,038 +121,097	+276%	+$2.39M	0.27%	136
2018 Q3	$845K	Sell	43,941 -855	-2%	-$15.2K	0.05%	226
2018 Q2	$684K	Sell	44,796 -7,621	-15%	-$133K	0.05%	232
2018 Q1	$983K	Hold	52,417	–	–	0.07%	205
2017 Q4	$1.01M	Hold	52,417	–	–	0.08%	208
2017 Q3	$937K	Hold	52,417	–	–	0.08%	201
2017 Q2	$936K	Hold	52,417	–	–	0.09%	187
2017 Q1	$760K	Buy	+52,417	New	+$824K	0.07%	207

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Matarin Capital Management's AMPH Position: Q1 2020 in Review

Matarin Capital Management sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2020, closing a stake of 121,359 shares — an estimated $2.34M sold.

Matarin Capital Management first reported a position in AMPH in Q1 2017 and held it in 12 quarters. The position peaked at $5M in Q2 2019. 111 funds tracked by Wall St. Rank hold AMPH as of Q1 2020.

Matarin Capital Management reported no remaining Amphastar Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Matarin Capital Management sold 121,359 Amphastar Pharmaceuticals shares in Q1 2020, an estimated $2.34M.
Matarin Capital Management first reported a position in Amphastar Pharmaceuticals in Q1 2017 and held it in 12 quarters.
Matarin Capital Management's Amphastar Pharmaceuticals position peaked at $5M in Q2 2019.
111 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2020.

Based on Matarin Capital Management's 13F filing for Q1 2020, filed 27 Apr 2020.